Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

<p>Supplemental Figure 5: Combination therapy of XVir-N-31 and CDK4/6 inhibitor LEE011 induces calreticulin (CALR) surface expression and increases phagocytosis in vitro.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Sebastian Johannes Schober (14971891) (author)
Andere auteurs:	Caroline Schoening (14971894) (author), Jennifer Eck (14971897) (author), Charlotte Middendorf (14971900) (author), Julia Lutsch (14971903) (author), Pia Knoch (14971906) (author), Anna Josefine von Ofen (14971909) (author), Hendrik Gassmann (14971912) (author), Melanie Thiede (14971915) (author), Julia Hauer (14971918) (author), Andreas Kolk (14971921) (author), Klaus Mantwill (14971924) (author), Jürgen E. Gschwend (14971927) (author), Stefan E.G. Burdach (14971930) (author), Roman Nawroth (14971933) (author), Uwe Thiel (14971936) (author), Per Sonne Holm (14971939) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Therapeutic Research and Development Immuno-oncology Immunotherapy Combination immunotherapy Pediatric Cancers Sarcomas Translational Research
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
door: Kankan Cao (16437263)
Gepubliceerd in: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
door: Li-Li Long (14963775)
Gepubliceerd in: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
door: Sahar Mafi (16721657)
Gepubliceerd in: (2025)

Supplementary Fig. S2 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
door: Sahar Mafi (16721657)
Gepubliceerd in: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
door: Daniel S. Green (15047598)
Gepubliceerd in: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Diversity of augmented graphs.
door: Hossein Rafieizadeh (22676722)
Gepubliceerd in: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
door: Arianna Draghi (15126339)
Gepubliceerd in: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
door: Arianna Draghi (15126339)
Gepubliceerd in: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
door: Arianna Draghi (15126339)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_n5alogedc6ljdn2d1237tul4nf